Expert Interview
Discussing the phase 1/2 clinical trial data on KYV-101 and CABA-201, two CAR-T therapies being developed for the treatment of autoimmune diseases.
Ticker(s): KYTX, CABAInstitution: Northwell Health
- Chief of the Division of Rheumatology at Northwell Health.
- Directs The Program in Novel Therapeutics, the Health System’s clinical research program in musculoskeletal disease and the Hospital’s SLE and Autoimmune Disease Treatment Center, which has become internationally recognized for its role in the development of new therapies for SLE.
- Treats 200+ patients with Lupus Nephritis.
- Clinical research in the area of anti-rheumatic drug development.
What is your professional background and current clinical practice, and what volume of lupus patients do you see monthly?
Can you provide an overview of the unmet need in lupus treatment, specifically lupus nephritis, and the potential role of CAR-T therapies in addressing these needs?
What are your thoughts on the differences between Cabaletta Bio’s CABA-201 and Kyverna’s KYV-101 products, particularly in terms of co-stimulatory domains and safety?
How do you assess the efficacy and safety data from the German and Chinese CAR-T studies, and what implications do they have for U.S.-based CAR-T development programs?
Added By: slingshot_adminWhat are your thoughts on the recent safety concerns, including ICANs and CRS, in CAR-T therapies, and how should the lupus community proceed with these treatments?
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
